nelfinavir (viracept) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Nelfinavir is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir is marketed under the brand name Viracept.   NCATS

Chemistry

  • SMILES: Cc1c(O)cccc1C(=O)N[C@@H](CSc2ccccc2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C
  • InChIKey: QAGYKUNXZHXKMR-HKWSIXNMSA-N
  • Mol. Mass: 567.8
  • ALogP: 4.75
  • ChEMBL Molecules:
    nelfinavir  
    nelfinavir mesylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2.9547 - $9.9642
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ag-1343 | nelfinavir | nelfinavir mesilate | nelfinavir mesylate | viracept

Organizations (72)

Research & Development (72)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (51)

Approved Indications (2)


 

HIV Infections

Post-Exposure Prophylaxis

Experimental Indications - Clinical Trial Phases 1-4 (50)


 

AIDS-Associated Nephropathy (Phase 3)

Brain Neoplasms (Phase 1)

Carcinoma, Adenoid Cystic (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiopulmonary Bypass (Phase 1)

Cardiovascular Diseases (Phase 4)

Castleman Disease (Early Phase 1)

Colorectal Neoplasms (Phase 1/Phase 2)

Cytomegalovirus Retinitis (Phase 2)

Diarrhea (Phase 3)

Endometrial Neoplasms (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 4)

Hepatitis C (Phase 4)

Herpesvirus 4, Human (Early Phase 1)

HIV (Phase 3)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

HIV Seronegativity (Phase 1)

Hodgkin Disease (Early Phase 1)

Immunity (Phase 1)

Infectious Disease Transmission, Vertical (Phase 3)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Lipodystrophy (Phase 4)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 1/Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Early Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Mycobacterium avium-intracellulare Infection (Phase 2)

Nasopharyngeal Neoplasms (Early Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pregnancy (Phase 3)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 2)

Sepsis (Phase 1)

Stomach Neoplasms (Early Phase 1)

Tuberculosis (Phase 4)

Uterine Cervical Dysplasia (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Vulvar Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 134
  • # of Trial Organizations: 72

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue